AGENUS INC (AGEN) Fundamental Analysis & Valuation

NASDAQ:AGEN • US00847G8042

Current stock price

4.09 USD
+0.19 (+4.87%)
At close:
4.0991 USD
+0.01 (+0.22%)
After Hours:

This AGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. AGEN Profitability Analysis

1.1 Basic Checks

  • AGEN had negative earnings in the past year.
  • In the past year AGEN has reported a negative cash flow from operations.
  • In the past 5 years AGEN always reported negative net income.
  • AGEN had negative operating cash flow in 4 of the past 5 years.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • AGEN has a better Return On Assets (-0.04%) than 87.38% of its industry peers.
Industry RankSector Rank
ROA -0.04%
ROE N/A
ROIC N/A
ROA(3y)-59.64%
ROA(5y)-47.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • AGEN has a Gross Margin of 99.11%. This is amongst the best in the industry. AGEN outperforms 98.45% of its industry peers.
  • In the last couple of years the Gross Margin of AGEN has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.56%
GM growth 5Y0.36%
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AGEN Health Analysis

2.1 Basic Checks

  • AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AGEN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AGEN has been increased compared to 5 years ago.
  • Compared to 1 year ago, AGEN has an improved debt to assets ratio.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -14.09, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
  • AGEN has a Altman-Z score of -14.09. This is amonst the worse of the industry: AGEN underperforms 80.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.09
ROIC/WACCN/A
WACC5.12%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M -300M

2.3 Liquidity

  • AGEN has a Current Ratio of 0.41. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AGEN has a worse Current ratio (0.41) than 93.20% of its industry peers.
  • A Quick Ratio of 0.41 indicates that AGEN may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.41, AGEN is doing worse than 93.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.41
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. AGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.25% over the past year.
  • Looking at the last year, AGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.37% in the last year.
  • The Revenue has been growing slightly by 5.31% on average over the past years.
EPS 1Y (TTM)96.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.75%
Revenue 1Y (TTM)10.37%
Revenue growth 3Y5.22%
Revenue growth 5Y5.31%
Sales Q2Q%27.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 33.81% on average over the next years. This is a very strong growth
  • AGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.44% yearly.
EPS Next Y634.16%
EPS Next 2Y-36.27%
EPS Next 3Y-57.64%
EPS Next 5Y33.81%
Revenue Next Year113.76%
Revenue Next 2Y7.39%
Revenue Next 3Y16.43%
Revenue Next 5Y20.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

4

4. AGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 1.91 indicates a rather cheap valuation of AGEN.
  • Based on the Price/Forward Earnings ratio, AGEN is valued cheaper than 99.81% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.23. AGEN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 1.91
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A cheap valuation may be justified as AGEN's earnings are expected to decrease with -57.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.27%
EPS Next 3Y-57.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGEN Dividend Analysis

5.1 Amount

  • No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGEN Fundamentals: All Metrics, Ratios and Statistics

AGENUS INC

NASDAQ:AGEN (4/27/2026, 8:00:00 PM)

After market: 4.0991 +0.01 (+0.22%)

4.09

+0.19 (+4.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners28.01%
Inst Owner Change-0.02%
Ins Owners1.63%
Ins Owner Change0.33%
Market Cap157.06M
Revenue(TTM)114.20M
Net Income(TTM)-101.00K
Analysts80
Price Target15.81 (286.55%)
Short Float %12.02%
Short Ratio7.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.56%
Min EPS beat(2)-3.94%
Max EPS beat(2)71.05%
EPS beat(4)2
Avg EPS beat(4)-16.59%
Min EPS beat(4)-172.44%
Max EPS beat(4)71.05%
EPS beat(8)4
Avg EPS beat(8)-17.31%
EPS beat(12)6
Avg EPS beat(12)-22.04%
EPS beat(16)9
Avg EPS beat(16)-12.92%
Revenue beat(2)1
Avg Revenue beat(2)-16.98%
Min Revenue beat(2)-46.8%
Max Revenue beat(2)12.83%
Revenue beat(4)1
Avg Revenue beat(4)-23.46%
Min Revenue beat(4)-49.33%
Max Revenue beat(4)12.83%
Revenue beat(8)1
Avg Revenue beat(8)-28.55%
Revenue beat(12)3
Avg Revenue beat(12)-12.94%
Revenue beat(16)7
Avg Revenue beat(16)2.12%
PT rev (1m)25.68%
PT rev (3m)25.68%
EPS NQ rev (1m)19.77%
EPS NQ rev (3m)27.66%
EPS NY rev (1m)40.31%
EPS NY rev (3m)40.31%
Revenue NQ rev (1m)65.38%
Revenue NQ rev (3m)25.36%
Revenue NY rev (1m)28.63%
Revenue NY rev (3m)29.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.91
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)2.14
Fwd EY52.37%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS2.97
BVpS-7.06
TBVpS-7.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.11%
FCFM N/A
ROA(3y)-59.64%
ROA(5y)-47.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.56%
GM growth 5Y0.36%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.06%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.41
Altman-Z -14.09
F-Score4
WACC5.12%
ROIC/WACCN/A
Cap/Depr(3y)25.88%
Cap/Depr(5y)267.94%
Cap/Sales(3y)2.31%
Cap/Sales(5y)14.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.75%
EPS Next Y634.16%
EPS Next 2Y-36.27%
EPS Next 3Y-57.64%
EPS Next 5Y33.81%
Revenue 1Y (TTM)10.37%
Revenue growth 3Y5.22%
Revenue growth 5Y5.31%
Sales Q2Q%27.45%
Revenue Next Year113.76%
Revenue Next 2Y7.39%
Revenue Next 3Y16.43%
Revenue Next 5Y20.44%
EBIT growth 1Y83.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-357.38%
EBIT Next 3Y-78.89%
EBIT Next 5Y-21.18%
FCF growth 1Y51.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.24%
OCF growth 3YN/A
OCF growth 5YN/A

AGENUS INC / AGEN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AGENUS INC?

ChartMill assigns a fundamental rating of 2 / 10 to AGEN.


What is the valuation status of AGENUS INC (AGEN) stock?

ChartMill assigns a valuation rating of 4 / 10 to AGENUS INC (AGEN). This can be considered as Fairly Valued.


How profitable is AGENUS INC (AGEN) stock?

AGENUS INC (AGEN) has a profitability rating of 2 / 10.


Can you provide the financial health for AGEN stock?

The financial health rating of AGENUS INC (AGEN) is 0 / 10.